| Name | Title | Contact Details |
|---|---|---|
Phillip Lee |
Chief Financial Officer | Profile |
Mersana is rewriting the rules for immunoconjugate therapies by leveraging our Fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients` lives. Our Fleximer platform allows us to custom design an ADC with specific properties to overcome limitations of current ADC approaches and increase the drug`s chances of effectively attacking a particular cancer. We engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. Because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, Mersana`s ADC therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today`s cancer treatments.
K Biosciences is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
New Hampshire Department of Resources and Economic Development is a Concord, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alliance Bio is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discovery Genomics is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.